673 related articles for article (PubMed ID: 28765854)
1. PSA testing for men at average risk of prostate cancer.
Armstrong BK; Barry MJ; Frydenberg M; Gardiner RA; Haines I; Carter SM
Public Health Res Pract; 2017 Jul; 27(3):. PubMed ID: 28765854
[TBL] [Abstract][Full Text] [Related]
2. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.
; Grossman DC; Curry SJ; Owens DK; Bibbins-Domingo K; Caughey AB; Davidson KW; Doubeni CA; Ebell M; Epling JW; Kemper AR; Krist AH; Kubik M; Landefeld CS; Mangione CM; Silverstein M; Simon MA; Siu AL; Tseng CW
JAMA; 2018 May; 319(18):1901-1913. PubMed ID: 29801017
[TBL] [Abstract][Full Text] [Related]
3. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians.
Qaseem A; Barry MJ; Denberg TD; Owens DK; Shekelle P;
Ann Intern Med; 2013 May; 158(10):761-769. PubMed ID: 23567643
[TBL] [Abstract][Full Text] [Related]
4. Relevance of total PSA and free PSA prescriptions.
Lamy PJ; Brouillet JP; Bermont L; Fouillet G; Loric S
Ann Biol Clin (Paris); 2018 Dec; 76(6):659-663. PubMed ID: 30543191
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
[TBL] [Abstract][Full Text] [Related]
6. Deliberative democracy and cancer screening consent: a randomised control trial of the effect of a community jury on men's knowledge about and intentions to participate in PSA screening.
Thomas R; Glasziou P; Rychetnik L; Mackenzie G; Gardiner R; Doust J
BMJ Open; 2014 Dec; 4(12):e005691. PubMed ID: 25539779
[TBL] [Abstract][Full Text] [Related]
7. Primary goals, information-giving and men's understanding: a qualitative study of Australian and UK doctors' varied communication about PSA screening.
Pickles K; Carter SM; Rychetnik L; McCaffery K; Entwistle VA
BMJ Open; 2018 Jan; 8(1):e018009. PubMed ID: 29362252
[TBL] [Abstract][Full Text] [Related]
8. Doctors' approaches to PSA testing and overdiagnosis in primary healthcare: a qualitative study.
Pickles K; Carter SM; Rychetnik L
BMJ Open; 2015 Mar; 5(3):e006367. PubMed ID: 25783420
[TBL] [Abstract][Full Text] [Related]
9. Men's preferences and trade-offs for prostate cancer screening: a discrete choice experiment.
Howard K; Salkeld GP; Patel MI; Mann GJ; Pignone MP
Health Expect; 2015 Dec; 18(6):3123-35. PubMed ID: 25382490
[TBL] [Abstract][Full Text] [Related]
10. The impact of the United States Preventive Services Task Force (USPTSTF) recommendations against prostate-specific antigen (PSA) testing on PSA testing in Australia.
Zargar H; van den Bergh R; Moon D; Lawrentschuk N; Costello A; Murphy D
BJU Int; 2017 Jan; 119(1):110-115. PubMed ID: 27454454
[TBL] [Abstract][Full Text] [Related]
11. [Prostate cancer screening using prostate-specific antigen: The views of general and laboratory physicians].
Giménez N; Filella X; Gavagnach M; Allué JA; Pedrazas D; Ferrer F;
Semergen; 2018 Sep; 44(6):409-419. PubMed ID: 29574008
[TBL] [Abstract][Full Text] [Related]
12. A Community Jury on PSA screening: what do well-informed men want the government to do about prostate cancer screening--a qualitative analysis.
Rychetnik L; Doust J; Thomas R; Gardiner R; Mackenzie G; Glasziou P
BMJ Open; 2014 Apr; 4(4):e004682. PubMed ID: 24785399
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline.
Tikkinen KAO; Dahm P; Lytvyn L; Heen AF; Vernooij RWM; Siemieniuk RAC; Wheeler R; Vaughan B; Fobuzi AC; Blanker MH; Junod N; Sommer J; Stirnemann J; Yoshimura M; Auer R; MacDonald H; Guyatt G; Vandvik PO; Agoritsas T
BMJ; 2018 Sep; 362():k3581. PubMed ID: 30185545
[No Abstract] [Full Text] [Related]
14. General Practitioners' Experiences of, and Responses to, Uncertainty in Prostate Cancer Screening: Insights from a Qualitative Study.
Pickles K; Carter SM; Rychetnik L; McCaffery K; Entwistle VA
PLoS One; 2016; 11(4):e0153299. PubMed ID: 27100402
[TBL] [Abstract][Full Text] [Related]
15. Do Men Receive Information Required for Shared Decision Making About PSA Testing? Results from a National Survey.
Leyva B; Persoskie A; Ottenbacher A; Hamilton JG; Allen JD; Kobrin SC; Taplin SH
J Cancer Educ; 2016 Dec; 31(4):693-701. PubMed ID: 26498649
[TBL] [Abstract][Full Text] [Related]
16. PSA testing for prostate cancer: an online survey of the views and reported practice of General Practitioners in the UK.
Brett J; Watson E; Hewitson P; Bukach C; Edwards A; Elwyn G; Austoker J
BMC Fam Pract; 2005 Jun; 6(1):24. PubMed ID: 15946386
[TBL] [Abstract][Full Text] [Related]
17. Use of the prostate-specific antigen test in the U.S. for men age 30 to 64 in 2011 to 2017 using a large commercial claims database: Implications for practice interventions.
Shahangian S; Sharma KP; Fan L; Siegel DA
Cancer Rep (Hoboken); 2021 Aug; 4(4):e1365. PubMed ID: 33934557
[TBL] [Abstract][Full Text] [Related]
18. Factors influencing primary care physicians' decision to order prostate-specific antigen (PSA) test for men without prostate cancer.
Hayat Roshanai A; Nordin K; Berglund G
Acta Oncol; 2013 Nov; 52(8):1602-8. PubMed ID: 23421929
[TBL] [Abstract][Full Text] [Related]
19. Doctors' perspectives on PSA testing illuminate established differences in prostate cancer screening rates between Australia and the UK: a qualitative study.
Pickles K; Carter SM; Rychetnik L; Entwistle VA
BMJ Open; 2016 Dec; 6(12):e011932. PubMed ID: 27920082
[TBL] [Abstract][Full Text] [Related]
20. The role of modelling in the policy decision making process for cancer screening: example of prostate specific antigen screening.
Getaneh AM; Heijnsdijk EA; de Koning HJ
Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
